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illusTraTive case 
An 85-year-old woman with hypertension 
and chronic atrial fibrillation has transferred 
her care to you. She takes an aspirin a 
day for cardiovascular prevention. You 
know that warfarin is better than aspirin 
for preventing stroke but worry about the 
increased risk of bleeding with warfarin. 
Should you recommend that she 
stay on aspirin or switch to warfarin? 
Background 
z	BAFTA:	A	realistic	study
We have been reluctant to use warfarin 
in elders with atrial fibrillation for good 
reason: risk of hemorrhage. Since there 
are few trials looking at use of warfarin 
among elders in primary care settings, 
we are uncertain about the balance of 
benefits and harms. 
The BAFTA study1 is the first trial 
to compare outcomes of warfarin vs 
aspirin in elders specifically, in the less-
than-ideal conditions of real life. 
Guidelines	mirror	uncertainties
This uncertainty is reflected even in 
guidelines for anticoagulation in elder-
ly patients with atrial fibrillation. 
• The 2004 American College of 
Chest Physicians Seventh Conference 
on Antithrombotic and Thrombolytic 
Therapy recommends treating all pa-
tients with atrial fibrillation and high 
risk of stroke with warfarin. Their defi-
nition of high-risk includes any patient 
with 1 or more of the following risk 
factors: age >75 years, prior ischemic 
stroke, transient ischemic attack or 
systemic embolism, congestive heart 
failure, impaired left ventricular systol-
ic function, hypertension, or diabetes 
mellitus.2 
• In contrast, the 2006 guidelines for 
the management of patients with atrial 
fibrillation from the American College 
of Cardiology, American Heart Associa-
tion, and European Society of Cardiol-
ogy, are more conservative. They rec-
ommend that patients with more than 
1 risk factor take warfarin, and patients 
with only 1 risk factor (for example, a 
patient older than 75 years of age with 
no other risk factors) take either warfa-
rin or aspirin.3 
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Warfarin was  
superior to aspirin 
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m
o
ll
Y
 b
o
r
m
A
N
 ©
 2
00
7
Age	alone	does	not		
preclude	warfarin
The key finding  
from the bAFTA  
study is that 
advanced age  
alone is not a  
contraindication  
to the use of  
warfarin for stroke 
prevention in  
elderly patients  
with atrial  
fibrillation
clinical conTexT
z		Reasonable	concerns
Fewer than half of the 10% to 12% of 
people older than 75 with atrial fibril-
lation are taking warfarin for stroke 
prevention. In one study, only 35% of 
patients 85 years and older with no 
known contraindication to anticoagula-
tion received warfarin.4 Possible reasons 
for this low rate include:
• cost of monitoring warfarin
• concerns about compliance
• increased risk of hemorrhage 
• prior studies focused on younger 
patients, in closely monitored settings. 
These factors lead us to speculate 
that many physicians believe that the 
risks of warfarin in elderly patients in 
primary care settings outweigh any po-
tential benefit. 
We think this study demonstrates 
that we should seriously discuss and con-
sider warfarin therapy for most of our 
elderly patients with atrial fibrillation.
sTudy summary 
z		Primary	care	setting,		
elders	only
This prospective randomized open-
label trial was designed to test the 
effectiveness and safety of warfarin vs 
aspirin in the elderly, in a realistic pri-
mary care setting. The study compared 
the frequency of stroke, intracranial 
hemorrhage, and other significant arte-
rial embolism in patients taking either 
warfarin or aspirin. 
inclusion criteria. Patients were at 
least 75 years old (average 81.5 years) 
with an ECG within the previous 2 
years showing atrial fibrillation or atri-
al flutter. Seventy percent of the patients 
had been previously diagnosed with 
atrial fibrillation and 30% were identi-
fied because they had an irregular pulse 
on exam. 
exclusion criteria included rheumatic 
heart disease, major nontraumatic hem-
orrhage in the past 5 years, intracranial 
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hemorrhage, endoscopically proven pep-
tic ulcer disease in the past year, esopha-
geal varices, allergy to either study drug, 
terminal illness, surgery in past 3 months, 
blood pressure greater than 180/110 mm 
Hg, or if the primary physician judged 
that a patient should either be on warfa-
rin or not, based on risk factors. 
Patient characteristics. The patients 
were recruited from 260 general prac-
tices in England and Wales. At baseline, 
39% to 40% of the patients were already 
taking warfarin, 12% to 13% had had a 
prior stroke, 53% to 55% had hyperten-
sion, 13% to 14% had diabetes, 19% to 
20% had heart failure, and 10% to 12% 
had a history of myocardial infarction. 
Patients were followed for an average of 
2.7 years.
aspirin and warfarin regimens. Patients 
were assigned to either aspirin at a dose 
of 75 mg/day or warfarin with a target 
international normalized ratio (INR) of 
2.5 and an acceptable range of 2 to 3. Be-
cause the study aimed to reflect a realistic 
primary care setting, the frequency and 
method of INR testing was left to the dis-
cretion of participating physicians. 
Patients who had been taking aspirin 
or warfarin prior to the study discontin-
ued that medicine if they were assigned 
to the other treatment. Sixty-seven per-
cent of the patients assigned to warfa-
rin continued this treatment throughout 
the study, and 78% of those who either 
stopped taking warfarin or never started 
it were put on either aspirin or clopido-
grel. Seventy-six percent of the patients 
assigned to aspirin took the medicine 
for the entire study period, while 70% 
of those who stopped taking aspirin or 
never started it were either switched to or 
stayed on warfarin. 
inr values. Patients on warfarin had 
INR values between 2.0 and 3.0 for 67% 
of the time, below range for 19%, of the 
time, and above range for 14% of the 
time. Twenty-two percent of practices 
had all components of INR monitoring 
done at the hospital (phlebotomy, INR 
analysis, and warfarin dosing), 19% of 
the practices completed all 3 components 
on site, and the remaining practices had 
various combinations of onsite and hos-
pital monitoring. 
The primary outcomes included dis-
abling stroke (ischemic or hemorrhagic) 
or clinically significant arterial embolism. 
There were 24 primary events (1.8% per 
year) in patients assigned to warfarin 
compared with 48 primary events (3.8% 
per year) in those assigned to aspirin, 
with a relative risk of 0.48 (95% confi-
dence interval [CI], 0.28–0.80 (TABLE). 
The number needed to treat for 1 year 
to prevent 1 primary event was 50, 
when  warfarin was compared to aspi-
rin. Warfarin was superior to aspirin in 
BAFTA is the first 
randomized  
controlled trial 
of warfarin vs 
aspirin for atrial 
fibrillation that 
included only  
patients 75 years 
and older,  
in a primary care  
setting
BAFTA	study:	Warfarin	was	as	safe	as	aspirin		
and	more	effective	in	preventing	stroke	in	the	elderly
 Warfarin  asPirin 
 (488 patients)  (485 patients) 
Primary Total Risk per  Total Risk per Warfarin 
evenTs events year events year vs asPirin
stroke 21 1.6% 44 3.4%  rr=0.46 
(95% CI, 0.26–0.79) P=.003
stroke, other intracranial 24 1.8% 48 3.8% rr=0.48  
hemorrhage, or systemic     (95% CI, 0.28–0.80) P=.003 
embolism 
rr, relative risk; CI, confidence interval.
Source: mant J, Hobbs FD, Fletcher K et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation 
(the birmingham Atrial Fibrillation Treatment of the Aged Study, bAFTA): a randomised controlled trial. Lancet 2007; 370:493–503.
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Warfarin vs aspirin
all subgroup analyses, including patients 
over 85 years old.
secondary outcomes. There were no 
significant differences between the war-
farin and aspirin groups in the secondary 
outcomes: hospital admission or death 
as a result of a non-stroke vascular event 
(6.1% risk per year with warfarin vs 
6.3% risk per year with aspirin), all-cause 
mortality (8.0% vs 8.4%), and major ex-
tracranial hemorrhage (1.4% vs 1.6%). 
Patients assigned to warfarin, including 
the subgroup of patients older than 85, 
did not have an increased risk of a ma-
jor hemorrhage when compared with 
those assigned to aspirin (1.9% risk per 
year with warfarin vs 2.0% risk per year 
with aspirin; relative risk=0.96; 95% CI, 
0.53–1.75).1
WhaT’s neW? 
z		Age	alone	does		
not	preclude	warfarin
The key finding from the BAFTA study 
is that advanced age alone is not a con-
traindication to the use of warfarin for 
stroke prevention in elderly patients with 
atrial fibrillation. 
This is the first randomized controlled 
trial of warfarin for atrial fibrillation that 
included only patients ages 75 and older, 
conducted in a primary care setting.5
limitations of earlier studies. The most 
recent meta-analysis of antithrombotic 
therapy for stroke prevention in patients 
with atrial fibrillation included 29 tri-
als with 28,044 patients. This analysis 
concluded that although both warfarin 
and aspirin are effective in reducing the 
risk of stroke in patients with atrial fi-
brillation (warfarin by 60% and aspirin 
by 20%), warfarin was more effective 
than aspirin (relative risk reduction of 
39%), with very small (≤0.3% per year) 
absolute increases in major extracranial 
hemorrhage. 
The average age of patients in 
those trials, however, was 71. The au-
thors identified the lack of data on 
older patients (who are at higher risk 
Keep the patient’s 
INR under 3.0  
and watch for 
signs of bleeding,  
especially in the 
first 90 days of 
warfarin therapy
for serious bleeding events) as a limi-
tation of the meta-analysis. Many of 
these trials took place in settings with 
closer monitoring of INR and warfarin 
dosing than is customary in a primary 
care setting.5 
caveaTs 
z		Consider	the	evidence	
on	benefits	and	risks
Major bleeding from warfarin is a con-
cern, especially in the elderly. A recent co-
hort study6 (summarized as a POEM in 
this journal7) reported high rates of major 
bleeding (13.1 per hundred person-years 
or 13.1%) in patients ≥80 years of age 
during their first year of warfarin therapy. 
Despite the high risk of bleeding events in 
this cohort study, there was considerable 
benefit from warfarin therapy.
None of the patients who remained 
on warfarin had a thrombotic stroke (per-
sonal communication with Dr Hylek by 
the author). The expected rate of throm-
botic stroke is in the range of 5% to 6% 
per year in this high-risk group. 
Furthermore, most of the bleeding 
events were gastrointestinal and did not 
lead to catastrophic outcomes. 
Do	not	add	warfarin		
to	aspirin	in	patients	>75	years
Dr Hylek also noted that 40% of the pa-
tients in their cohort study were taking 
both warfarin and aspirin, and, although 
her study did not have sufficient power 
to detect a difference, prior studies noted 
increased risk of bleeding with this com-
bination compared to warfarin alone.8,9 
For this reason we think the combination 
of warfarin and aspirin should be avoid-
ed in patients over 75. 
Target	INR	<3	
Our caveat is the same as the POEM 
author’s conclusion:7 Patients over 80 
should be carefully monitored to keep the 
INR below 3.0 or for signs of bleeding, 
especially in the first 90 days of therapy 
when bleeding is more likely to occur. 
C o N T I N u e D
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A final point that the BAFTA au-
thors make, which is worth repeating 
here, is that the prior studies showing 
an increased risk of bleeding complica-
tions had INR target rates of 4 to 5, 
whereas the target in this study was 
2 to 3. Two previous studies that also 
compared aspirin to warfarin with an 
INR goal of 2 to 3 similarly showed no 
difference in major bleeding between 
the 2 groups.10,11
challenges To imPlemenTaTion 
z		Meticulous	monitoring,		
patient	education	
• managing warfarin therapy requires 
meticulous care to avoid complications 
and optimize treatment effect. 
• Patients may be reluctant to take war-
farin because they may fear bleeding. 
• Patients who do agree to take warfa-
rin need education about possible medi-
cation interactions, the need for regular 
INR monitoring, dosage changes, and di-
etary issues (eg, maintaining a consistent 
intake of foods containing vitamin K). 
Contraindications
Contraindications to the use of warfarin 
include hypersensitivity to warfarin, se-
vere hepatic disease, alcoholism, recent 
trauma or surgery, history of falling or 
significant risk of falls, and active gastro-
intestinal, respiratory, or genitourinary 
bleeding. 
z	INR	testing	systems
Several randomized trials support the 
use of monitoring systems such as a 
pharmacist managed anticoagulation 
service or decision support software, 
both of which can improve the per-
centage of patients with therapeutic 
INR values.12,13 
Using point-of-care INR tests in the 
office provides immediate results which 
allow for more timely adjustments of 
warfarin dose.14  n
Purls methodology
This study was selected and evaluated using the Family Physician 
Inquiries Network’s Priority updates from the research literature 
Surveillance System (Purls) methodology. The criteria and find-
ings leading to the selection of this study as a Purl can be ac-
cessed at www.jfponline.com/purls.
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